Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Hits $566.37 Million By 2020: Grand View Research, Inc.

Global ITP therapeutics market is expected to reach USD 566.37 million by 2020, according to a new study by Grand View Research, Inc. Introduction of new drugs especially pertaining to TPO-RA and IVIG classes is expected to serve this market as a high impact rendering driver. Presence of favorable government regulations such as the Orphan Drug Act in the U.S. aimed at encouraging new product development is expected to have a positive impact on the market. Most notable trend observed in this market is an increase in demand for combination therapies involving two or more drugs. Clinical evidences suggest that some combination therapies prove to be cost effective, exhibit higher efficacies and help curb side effects otherwise associated with individual therapeutic classes.

Corticosteroids are the most frequently administered therapy for idiopathic thrombocytopenic purpura (ITP). The global corticosteroids market for ITP was valued at over USD 125.0 million in 2013. Corticosteroids are considered as the first line of treatment in patients with ITP and therefore, enjoy very high usage rates.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/idiopathic-thrombocytopenic-purpura-itp-therapeutics

For More Information visit - http://www.grandviewresearch.com/